Sugi Predict

Sugi Predict / Compounds / SCHEMBL217685

SCHEMBL217685

SCHEMBL217685

CON(C)C(=O)c1ccc2cc[nH]c2c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.57
▸ HSD17B10 Q99714 3/20 0.57
▸ KDM4E B2RXH2 2/20 0.57
▸ HPGD P15428 2/20 0.57
▸ ENPP2 Q13822 1/20 0.57
▸ MEN1 O00255 1/20 0.46
▸ POLB P06746 1/20 0.46
▸ MAPK1 P28482 1/20 0.46
▸ KMT2A Q03164 1/20 0.46
▸ TAS1R3 Q7RTX0 1/20 0.46
▸ TAS1R1 Q7RTX1 1/20 0.46
▸ MAOA P21397 2/20 0.45
▸ GHSR Q92847 3/20 0.44
▸ MAPT P10636 3/20 0.43
▸ MLYCD O95822 1/20 0.42
▸ TYR P14679 1/20 0.42
▸ ESR1 P03372 3/20 0.42
▸ ALOX12 P18054 1/20 0.41
▸ TUBB4A P04350 1/20 0.41
▸ TUBB P07437 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30440183 1.00 ALDH1A1 (0.57) ALDH1A1HSD17B10KDM4EHPGDENPP2
SCHEMBL3734056 0.88 TUBB4A (0.53) TAS1R3TAS1R1MAOAMAPTMLYCD
SCHEMBL828241 0.84 ALDH1A1 (0.64) ALDH1A1HSD17B10KDM4EHPGDENPP2
SCHEMBL30201504 0.78 ALDH1A1 (0.64) ALDH1A1HSD17B10KDM4EHPGDENPP2
SCHEMBL145507 0.78 ALDH1A1 (0.64) ALDH1A1HSD17B10KDM4EHPGDENPP2
SCHEMBL5484862 0.77 OPRM1 (0.60) ALDH1A1HSD17B10KDM4EHPGDENPP2
SCHEMBL7884484 0.77 ALDH1A1 (0.54) ALDH1A1HSD17B10KDM4EHPGDENPP2
SCHEMBL19763355 0.76 MLYCD (0.45) ALDH1A1HSD17B10KDM4EHPGDMLYCD
SCHEMBL15066548 0.76 MLYCD (0.42) MEN1KMT2AMAPTMLYCD
Hydrochloric Acid SCHEMBL28263913 0.76 ALDH1A1 (0.62) ALDH1A1HSD17B10KDM4EHPGDENPP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240300956-A1 IMIDAZO[1,2-B][1,2,4]TRIAZOL DERIVATIVES FOR USE IN THERAPY SANOFI (FR) 2024-09-12 — — US disclosed
WO-2024117179-A1 KIT INHIBITORS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF ALIVEXIS, INC. (JP) 2024-06-06 — — WO disclosed
EP-4370518-A1 IMIDAZO[1,2-B][1,2,4]TRIAZOL DERIVATIVES FOR USE IN THERAPY Sanofi (FR) 2024-05-22 — — EP disclosed
CN-117916240-A Imidazo [1,2-b ] [1,2,4] triazole derivatives for use in therapy 赛诺菲 2024-04-19 — — CN disclosed
US-20230144767-A1 TARGETED NITROXIDE AGENTS UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2023-05-11 — — US disclosed
US-20230144767-A1 TARGETED NITROXIDE AGENTS UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2023-05-11 — — US disclosed
US-20230144767-A1 TARGETED NITROXIDE AGENTS UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2023-05-11 — — US disclosed
WO-2023285466-A1 IMIDAZO[1,2-B][1,2,4]TRIAZOL DERIVATIVES FOR USE IN THERAPY SANOFI (FR) 2023-01-19 — — WO disclosed
US-20210371460-A1 TARGETED NITROXIDE AGENTS UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2021-12-02 — — US disclosed
US-20210371460-A1 TARGETED NITROXIDE AGENTS UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2021-12-02 — — US disclosed
US-7468446-B2 Substituted heterocyclic compounds and uses thereof CELGENE CORPORATION (US) 2008-12-23 — — US disclosed
US-20080096913-A1 PPAR active compounds PLEXXIKON, INC. 2008-04-24 — — US disclosed
US-20080096913-A1 PPAR active compounds PLEXXIKON, INC. 2008-04-24 — — US disclosed
US-20070155818-A1 PPAR ACTIVE COMPOUNDS PLEXXIKON, INC. 2007-07-05 — — US disclosed
US-20070155818-A1 PPAR ACTIVE COMPOUNDS PLEXXIKON, INC. 2007-07-05 — — US disclosed
US-20070149603-A1 PPAR ACTIVE COMPOUNDS PLEXXIKON, INC. 2007-06-28 — — US disclosed
US-20070149603-A1 PPAR ACTIVE COMPOUNDS PLEXXIKON, INC. 2007-06-28 — — US disclosed
EP-1794139-A2 SUBSTITUTED HETEROCYCLIC COMPOUNDS AND USES THEREOF CELGENE CORPORATION (US) 2007-06-13 — — EP disclosed
WO-2006028963-A2 SUBSTITUTED HETEROCYCLIC COMPOUNDS AND USES THEREOF CELGENE CORPORATION (US) 2006-03-16 — — WO disclosed
US-20060052596-A1 Substituted heterocyclic compounds and uses thereof CELGENE CORPORATION 2006-03-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080096913-A1 PPAR active compounds PPARG, PPARD, PPARA ALDH1A1 1171/4885HSD17B10 290/4885KDM4E 2954/4885
US-20060052596-A1 Substituted heterocyclic compounds and uses thereof NQO1, LTC4S, VHL ALDH1A1 111/4885HSD17B10 560/4885KDM4E 1674/4885
US-20230144767-A1 TARGETED NITROXIDE AGENTS TXNRD2, TXN2, HSPE1 ALDH1A1 2264/4885HSD17B10 1423/4885KDM4E 2171/4885
US-20070149603-A1 PPAR ACTIVE COMPOUNDS PPARG, PPARD, PPARA ALDH1A1 1171/4885HSD17B10 290/4885KDM4E 2954/4885
US-20210371460-A1 TARGETED NITROXIDE AGENTS TXNRD2, TXN2, HSPE1 ALDH1A1 2264/4885HSD17B10 1423/4885KDM4E 2171/4885
US-20070155818-A1 PPAR ACTIVE COMPOUNDS PPARG, PPARD, PPARA ALDH1A1 1171/4885HSD17B10 290/4885KDM4E 2954/4885
US-20240300956-A1 IMIDAZO[1,2-B][1,2,4]TRIAZOL DERIVATIVES FOR USE IN THERAPY H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HRAS, AADAC ALDH1A1 95/4885HSD17B10 703/4885KDM4E 4086/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.